Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, and Clinical Activity Study of a Single Dose of JAG201 Gene Therapy Delivered Via Intracerebroventricular Administration in Participants With SHANK3 Haploinsufficiency

NCT06662188 is registered in ClinicalTrials.gov with Jaguar Gene Therapy, LLC as lead sponsor.

NCT NCT06662188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06662188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, and Clinical Activity Study of a Single Dose of JAG201 Gene Therapy Delivered Via Intracerebroventricular Administration in Participants With SHANK3 Haploinsufficiency
Lead sponsor
Jaguar Gene Therapy, LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 7, 2024
Completion date
June 30, 2031
Enrollment
6 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

phelan-mcdermid syndrome, shank3 haploinsufficiency